Tiziana Life Sciences Ltd TLSA
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 9.85M | 10.35M | 10.85M | 11.72M | 12.58M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 23.32M | 22.23M | 21.13M | 19.80M | 18.47M |
| Operating Income | -23.32M | -22.23M | -21.13M | -19.80M | -18.47M |
| Income Before Tax | -25.19M | -21.81M | -18.43M | -16.41M | -14.40M |
| Income Tax Expenses | -- | -- | -- | -778.50K | -1.56M |
| Earnings from Continuing Operations | -25.19 | -21.81 | -18.43 | -15.64 | -12.84 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -25.19M | -21.81M | -18.43M | -15.64M | -12.84M |
| EBIT | -23.32M | -22.23M | -21.13M | -19.80M | -18.47M |
| EBITDA | -23.31M | -22.21M | -21.12M | -19.79M | -18.46M |
| EPS Basic | -0.20 | -0.18 | -0.16 | -0.13 | -0.11 |
| Normalized Basic EPS | -0.12 | -0.12 | -0.11 | -0.10 | -0.10 |
| EPS Diluted | -0.20 | -0.18 | -0.16 | -0.13 | -0.11 |
| Normalized Diluted EPS | -0.12 | -0.12 | -0.11 | -0.10 | -0.10 |
| Average Basic Shares Outstanding | 495.23M | 484.18M | 473.13M | 463.64M | 454.15M |
| Average Diluted Shares Outstanding | 495.23M | 484.18M | 473.13M | 463.64M | 454.15M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |